Literature DB >> 3524224

Cryptococcal infections in patients with acquired immune deficiency syndrome.

R H Eng, E Bishburg, S M Smith, R Kapila.   

Abstract

Cryptococcus neoformans is a major pathogen in patients with acquired immune deficiency syndrome and was found to infect 13.3 percent of such patients seen at two medical centers. Serum cryptococcal antigen levels were as high as 1:2,000,000 and, despite therapy, often remained elevated. Antigen titers in the cerebrospinal fluid generally declined at an expected rate in the survivors. The significance of high antigen titers in the blood after a prolonged course of therapy with amphotericin B and 5-flucytosine is unknown.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3524224     DOI: 10.1016/0002-9343(86)90176-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  72 in total

1.  Efficacy of SCH39304 in murine cryptococcosis.

Authors:  B I Restrepo; J Ahrens; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

2.  Pulmonary cryptococcosis.

Authors:  G B Huffnagle; M F Lipscomb
Journal:  Am J Pathol       Date:  1992-12       Impact factor: 4.307

3.  Laboratory techniques in the investigation of fungal infections.

Authors:  R J Hay
Journal:  Genitourin Med       Date:  1992-12

4.  Capsular Material of Cryptococcus neoformans: Virulence and Much More.

Authors:  A Vecchiarelli; C Monari
Journal:  Mycopathologia       Date:  2012-02-08       Impact factor: 2.574

5.  Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes.

Authors:  A Vecchiarelli; C Retini; C Monari; C Tascini; F Bistoni; T R Kozel
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

6.  Cryptococcosis in the AIDS era.

Authors:  D W Mackenzie
Journal:  Epidemiol Infect       Date:  1989-06       Impact factor: 2.451

7.  Aggregation of Cryptococcus neoformans by surfactant protein D is inhibited by its capsular component glucuronoxylomannan.

Authors:  J K van de Wetering; F E J Coenjaerts; A B Vaandrager; L M G van Golde; J J Batenburg
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  Anticryptococcal resistance in the mouse brain: beneficial effects of local administration of heat-inactivated yeast cells.

Authors:  E Blasi; R Mazzolla; R Barluzzi; P Mosci; F Bistoni
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

9.  Cavitating pulmonary cryptococcosis developing in an HIV antibody patient despite prior treatment with fluconazole.

Authors:  R J Coker; D Bell; B S Peters; S M Murphy
Journal:  Genitourin Med       Date:  1992-02

10.  Noise-induced hearing loss in mice treated with antiretroviral drugs.

Authors:  Devrim Bektas; Glen K Martin; Barden B Stagner; Brenda L Lonsbury-Martin
Journal:  Hear Res       Date:  2008-02-08       Impact factor: 3.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.